Subtle Variations in Pten Dose Determine Cancer Susceptibility

Overview

Journal Nat Genet

Specialty Genetics

Date 2010 Apr 20

PMID 20400965

Citations 295

Authors

Andrea Alimonti

Arkaitz Carracedo

John G Clohessy

Lloyd C Trotman

Caterina Nardella

Ainara Egia

Leonardo Salmena

Katia Sampieri

William J Haveman

Edi Brogi

Andrea L Richardson

Jiangwen Zhang

Pier Paolo Pandolfi

Affiliations

Soon will be listed here.

Abstract

Cancer susceptibility has been attributed to at least one heterozygous genetic alteration in a tumor suppressor gene (TSG). It has been hypothesized that subtle variations in TSG expression can promote cancer development. However, this hypothesis has not yet been definitively supported in vivo. Pten is a TSG frequently lost in human cancer and mutated in inherited cancer-predisposition syndromes. Here we analyze Pten hypermorphic mice (Pten(hy/+)), expressing 80% normal levels of Pten. Pten(hy/+) mice develop a spectrum of tumors, with breast tumors occurring at the highest penetrance. All breast tumors analyzed here retained two intact copies of Pten and maintained Pten levels above heterozygosity. Notably, subtle downregulation of Pten altered the steady-state biology of the mammary tissues and the expression profiles of genes involved in cancer cell proliferation. We present an alterative working model for cancer development in which subtle reductions in the dose of TSGs predispose to tumorigenesis in a tissue-specific manner.

Citing Articles

Potential of phosphatase and tensin gene polymorphisms as salivary biomarkers in oral squamous cell carcinoma - A cross-sectional study.

Narang B, Deshmukh R, Palaskar S, Bartake A, Patil S, Nitin P J Oral Maxillofac Pathol. 2025; 28(4):596-601.

PMID: 39949687 PMC: 11819637. DOI: 10.4103/jomfp.jomfp_118_24.

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review.

Zhong H, Zhou Z, Wang H, Wang R, Shen K, Huang R Int J Mol Sci. 2025; 25(24.

PMID: 39769140 PMC: 11677710. DOI: 10.3390/ijms252413376.

Suppressive cancer nonstop extension mutations increase C-terminal hydrophobicity and disrupt evolutionarily conserved amino acid patterns.

Ghosh A, Riester M, Pal J, Lainde K, Tangermann C, Wanninger A Nat Commun. 2024; 15(1):9209.

PMID: 39448564 PMC: 11502859. DOI: 10.1038/s41467-024-52779-4.

The implications of APOBEC3-mediated C-to-U RNA editing for human disease.

Van Norden M, Falls Z, Mandloi S, Segal B, Baysal B, Samudrala R Commun Biol. 2024; 7(1):529.

PMID: 38704509 PMC: 11069577. DOI: 10.1038/s42003-024-06239-w.

RNA m6A methylation and regulatory proteins in pulmonary arterial hypertension.

Wang Z, Zhang Y, Shi J, Yan Y, Zhao L, Kou J Hypertens Res. 2024; 47(5):1273-1287.

PMID: 38438725 DOI: 10.1038/s41440-024-01607-9.

References

Venkatachalam S, Shi Y, Jones S, Vogel H, Bradley A, Pinkel D . Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998; 17(16):4657-67. PMC: 1170795. DOI: 10.1093/emboj/17.16.4657. View

Trotman L, Alimonti A, Scaglioni P, Koutcher J, Cordon-Cardo C, Pandolfi P . Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006; 441(7092):523-7. PMC: 1976603. DOI: 10.1038/nature04809. View

Salmena L, Carracedo A, Pandolfi P . Tenets of PTEN tumor suppression. Cell. 2008; 133(3):403-14. DOI: 10.1016/j.cell.2008.04.013. View

Richardson A, Wang Z, De Nicolo A, Lu X, Brown M, Miron A . X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006; 9(2):121-32. DOI: 10.1016/j.ccr.2006.01.013. View

Di Cristofano A, Pandolfi P . The multiple roles of PTEN in tumor suppression. Cell. 2000; 100(4):387-90. DOI: 10.1016/s0092-8674(00)80674-1. View

Hong F, Breitling R, McEntee C, Wittner B, Nemhauser J, Chory J . RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 2006; 22(22):2825-7. DOI: 10.1093/bioinformatics/btl476. View

Friend S . Alfred Knudson: the importance of a visionary who enables scientists. Genes Chromosomes Cancer. 2003; 38(4):326-8. DOI: 10.1002/gcc.10257. View

Saal L, Holm K, Maurer M, Memeo L, Su T, Wang X . PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005; 65(7):2554-9. DOI: 10.1158/0008-5472-CAN-04-3913. View

Suzuki A, de la Pompa J, Stambolic V, Elia A, Sasaki T, del Barco Barrantes I . High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998; 8(21):1169-78. DOI: 10.1016/s0960-9822(07)00488-5. View

10.

Yan H, Dobbie Z, Gruber S, Markowitz S, Romans K, Giardiello F . Small changes in expression affect predisposition to tumorigenesis. Nat Genet. 2001; 30(1):25-6. DOI: 10.1038/ng799. View

11.

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

12.

Knudson A . Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996; 122(3):135-40. DOI: 10.1007/BF01366952. View

13.

Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O . HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003; 22(5):1134-46. PMC: 150350. DOI: 10.1093/emboj/cdg117. View

14.

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View

15.

Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R . Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002; 33(4):405-9. DOI: 10.1053/hupa.2002.124721. View

16.

Knudson A . Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2002; 1(2):157-62. DOI: 10.1038/35101031. View

17.

Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi P . Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998; 19(4):348-55. DOI: 10.1038/1235. View

18.

McDevitt M, Shivdasani R, Fujiwara Y, Yang H, Orkin S . A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A. 1997; 94(13):6781-5. PMC: 21235. DOI: 10.1073/pnas.94.13.6781. View

19.

Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O . Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 2005; 19(15):1779-86. PMC: 1182340. DOI: 10.1101/gad.1314405. View

20.

Podsypanina K, Ellenson L, Nemes A, Gu J, Tamura M, Yamada K . Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999; 96(4):1563-8. PMC: 15517. DOI: 10.1073/pnas.96.4.1563. View